{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:10:39Z","timestamp":1787760639719,"version":"build-2784847793"},"reference-count":56,"publisher":"Tech Science Press","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.067561","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T08:57:13Z","timestamp":1757062633000},"page":"2923-2935","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 Vaccine-Induced Seroconversion and Immune Correlates in Patients with Hematological Malignancies. A Real World Study"],"prefix":"10.32604","volume":"33","author":[{"given":"Norbert","family":"Nass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Kamal","family":"Yaakoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra-Victorita","family":"Simion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Pannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/v16020203","article-title":"COVID-19 vaccines: where did we stand at the end of 2023?","volume":"16","author":"Lundstrom","year":"2024","journal-title":"Viruses"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3000605221086155","DOI":"10.1177\/03000605221086155","article-title":"COVID-19 vaccination in cancer patients: a narrative review","volume":"50","author":"Seneviratne","year":"2022","journal-title":"J Int Med Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","article-title":"SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis","volume":"41","author":"Velikova","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","article-title":"Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review","volume":"33","author":"Corti","year":"2022","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/vaccines10020164","article-title":"COVID-19 vaccination in cancer patients older than 70 years undergoing active treatment. seroconversion rate and safety","volume":"10","author":"Cavanna","year":"2022","journal-title":"Vaccines"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000523753","article-title":"Vaccination for SARS-CoV-2 in hematological patients","volume":"145","author":"Riccardi","year":"2022","journal-title":"Acta Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"eAO0089","DOI":"10.31744\/einstein_journal\/2023AO0089","article-title":"Immunogenicity profile after COVID-19 vaccination in patients with onco-hematological diseases","volume":"21","author":"Almeida Neto","year":"2023","journal-title":"Einstein"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"892331","DOI":"10.3389\/fimmu.2022.892331","article-title":"Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients","volume":"13","author":"Pascale","year":"2022","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.vaccine.2023.01.072","article-title":"Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: a systematic review and meta-analysis","volume":"41","author":"Wankhede","year":"2023","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"101455","DOI":"10.1016\/j.arr.2021.101455","article-title":"Underrepresentation of older adults in clinical trials on COVID-19 vaccines: a systematic review","volume":"71","author":"Veronese","year":"2021","journal-title":"Ageing Res Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1144824","DOI":"10.3389\/fphar.2023.1144824","article-title":"COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/cei\/uxab015","article-title":"Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?","volume":"207","author":"Baker","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1138765","DOI":"10.3389\/fimmu.2023.1138765","article-title":"Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients","volume":"14","author":"Seree-Aphinan","year":"2023","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","article-title":"T cell responses to SARS-CoV-2","volume":"41","author":"Sette","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e004766","DOI":"10.1136\/jitc-2022-004766","article-title":"Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies","volume":"10","author":"Rouhani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"eabo1303","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","volume":"7","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1405217","DOI":"10.3389\/fimmu.2024.1405217","article-title":"Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults","volume":"15","author":"H-V\u00e1zquez","year":"2024","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/infdis\/jiae106","article-title":"Immunologic predictors of vaccine responsiveness in patients with lymphoma and chronic lymphocytic leukemia","volume":"230","author":"Chong","year":"2024","journal-title":"J Infect Dis"},{"key":"ref23","first-page":"CD013825","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"106822","DOI":"10.1016\/j.cct.2022.106822","article-title":"The comparative effectiveness of COVID-19 monoclonal antibodies: a learning health system randomized clinical trial","volume":"119","author":"McCreary","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"ofac172","DOI":"10.1093\/ofid\/ofac172","article-title":"Bamlanivimab and etesevimab improve symptoms and associated outcomes in ambulatory patients at increased risk for severe coronavirus disease 2019: results from the placebo-controlled double-blind phase 3 BLAZE-1 trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiac320","article-title":"Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19","volume":"227","author":"Somersan-Karakaya","year":"2022","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1087996","DOI":"10.3389\/fimmu.2023.1087996","article-title":"Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments","volume":"14","author":"Pfannes","year":"2023","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/cancers14061544","article-title":"Longitudinal humoral and cellular immune responses following SARS-CoV-2 vaccination in patients with myeloid and lymphoid neoplasms compared to a reference cohort: results of a prospective trial of the east German study group for hematology and oncology (OSHO)","volume":"14","author":"Jotschke","year":"2022","journal-title":"Cancers"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Diefenbach C, Caro J, Koide A, Grossbard M, Goldberg JD, Raphael B, et al. Impaired humoral immunity to SARS-CoV-2 vaccination in non-Hodgkin lymphoma and CLL patients. medRxiv. 2021:2021.06.02.2125780. doi:10.1101\/2021.06.02.21257804.","DOI":"10.1101\/2021.06.02.21257804"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"719140","DOI":"10.3389\/fonc.2021.719140","article-title":"Tumor microenvironment of lymphomas and plasma cell neoplasms: broad overview and impact on evaluation for immune based therapies","volume":"11","author":"Perincheri","year":"2021","journal-title":"Front Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/ijms23063368","article-title":"Effects of B-cell lymphoma on the immune system and immune recovery after treatment: the paradigm of targeted therapy","volume":"23","author":"Mancuso","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e002662","DOI":"10.1136\/jitc-2021-002662","volume":"9","author":"Wu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fimmu.2015.00258","article-title":"Impaired T-cell function in B-cell lymphoma: a direct consequence of events at the immunological synapse?","volume":"6","author":"Nassef Kadry Naguib Roufaiel","year":"2015","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"103635","DOI":"10.1016\/j.ebiom.2021.103635","article-title":"SARS-CoV-2 vaccination in multiple sclerosis: a clearer picture for the time point during CD20 depleting therapy","volume":"73","author":"Schulte","year":"2021","journal-title":"EBioMedicine"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"834981","DOI":"10.3389\/fimmu.2022.834981","article-title":"Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy","volume":"13","author":"Marty","year":"2022","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"763412","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/art.42034","article-title":"B cell reconstitution is strongly associated with COVID-19 vaccine responsiveness in rheumatic disease patients who received treatment with rituximab","volume":"74","author":"Jinich","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","article-title":"The link between circulating follicular helper T cells and autoimmunity","volume":"22","author":"Walker","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"eadh4529","DOI":"10.1126\/scitranslmed.adh4529","article-title":"T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19","volume":"15","author":"Zonozi","year":"2023","journal-title":"Sci Transl Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s15010-023-02171-z","article-title":"Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up","volume":"52","author":"Triebelhorn","year":"2024","journal-title":"Infection"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1186\/s12879-022-07722-7","article-title":"Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease","volume":"22","author":"Arnold","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.vaccine.2023.04.029","article-title":"Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: an observer-blinded, multi-center, phase 2 randomized trial","volume":"41","author":"Estephan","year":"2023","journal-title":"Vaccine"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/diseases12020033","article-title":"A descriptive, retrospective analysis of COVID-19 passive antibody therapy and its effects on morbidity and mortality in patients receiving B-cell-depleting therapies","volume":"12","author":"Gentile","year":"2024","journal-title":"Diseases"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-10\/OncolRes-33-10-67561\/OncolRes-33-67561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:21:50Z","timestamp":1763346110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n10\/63893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.067561","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}